<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209712</url>
  </required_header>
  <id_info>
    <org_study_id>DS2019070101</org_study_id>
    <nct_id>NCT04209712</nct_id>
  </id_info>
  <brief_title>Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease</brief_title>
  <official_title>Phase I Clinical Trial of Haploid Donor-derived in Vitro Activated Natural Killer Cells Infusion for Patients With Minimal Residual Disease After Consolidation Therapy for Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebei Yanda Ludaopei Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the effectiveness and safety of haploid donor-derived in vitro&#xD;
      activated natural killer(NK) cells infusion for Treating acute myeloid leukemia Patients With&#xD;
      minimal residual disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients of acute myeloid leukemia after chemotherapy with MRD(minimal residual disease) will&#xD;
      receive NK cell infusion combined with consolidation chemotherapy. The bone marrow morphology&#xD;
      and MRD remission of the patients will be observed 15 days after the same treatment. All&#xD;
      patients will be followed up for 1 year.&#xD;
&#xD;
      NK cells are prepared in Beijing iCELL Biotechnology Co.,Ltd, which is subsidiary to Shanghai&#xD;
      iCELL Biotechnology Co.,Ltd.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>haploid allogeneic NK cell therapy with chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimal Residual Disease (MRD)</measure>
    <time_frame>12 months</time_frame>
    <description>MRD-negative is defined as &lt;0.1% blasts with leukemia-associated phenotype detected by flow cytometry. MRD-positive is defined as &gt;=0.1% blasts with leukemia-associated phenotype detected by flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of toxicities defined as any CTCAE (v. 4.03)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>haploid allogeneic NK cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>haploid allogeneic NK cell therapy with chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>haploid allogeneic NK cell therapy</intervention_name>
    <description>NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.</description>
    <arm_group_label>haploid allogeneic NK cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with acute myeloid leukemia;&#xD;
&#xD;
          2. MRD after 2 course of standard chemotherapy;&#xD;
&#xD;
          3. No plan for hematopoietic stem cell transplantation;&#xD;
&#xD;
          4. Hemoglobin (Hb) &gt;=60g/L, white blood cell count (WBC) &gt;=2.5x10^9/L, platelet count&#xD;
             &gt;=30x10^9/L;&#xD;
&#xD;
          5. Patients have self-knowledge ability and can sign informed and voluntary consent&#xD;
             forms;&#xD;
&#xD;
          6. Patients or their clients, guardians of pediatric patients signed the informed and&#xD;
             voluntary consent form and joined the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intracranial hypertension or unconsciousness;&#xD;
&#xD;
          2. Symptomatic heart failure or severe arrhythmia;&#xD;
&#xD;
          3. Respiratory failure;&#xD;
&#xD;
          4. With other types of malignant tumor diseases;&#xD;
&#xD;
          5. T lymphocytic acute leukemia;&#xD;
&#xD;
          6. Diffuse intravascular;&#xD;
&#xD;
          7. Serum creatinine and / or urea nitrogen &gt;=1.5 times the normal value;coagulation;&#xD;
&#xD;
          8. Serum total bilirubin &gt;=1.5 times the normal value;&#xD;
&#xD;
          9. Sepsis or other difficult-to-control infections;&#xD;
&#xD;
         10. Uncontrollable diabetes;&#xD;
&#xD;
         11. severe mental disorders;&#xD;
&#xD;
         12. WHO physical status classification &gt;=3;&#xD;
&#xD;
         13. People who are allergic to Interleukin-2;&#xD;
&#xD;
         14. Patients after organ transplant;&#xD;
&#xD;
         15. Pregnant and lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xian Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang ZHU</last_name>
    <phone>+86-15900398802</phone>
    <email>zhujiang@icell.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hebei Yanda Ludaopei Hospital</name>
      <address>
        <city>Langfang</city>
        <state>Hebei</state>
        <zip>065201</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang ZHU</last_name>
      <phone>+86-15900398802</phone>
      <email>zhujiang@icell.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

